Stacey Condren, MD
Endocrinology, Diabetes & Metabolism · Vancouver, WANPI 1396703211
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $962 of the $1,087 with a category attached, or 88.5%. 7 manufacturers reported payments, led by Novo Nordisk at 41.1% of the total.
Across 14 payments — averaging $77.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- Tandem Diabetes Care, Inc.$175
- Ascendis Pharma Endocrinology Inc$124
- BETA Bionics, Inc.$124
- Dexcom, Inc.$85
- Amgen$71
- plus $60 from 1 others
Across 11 payments — averaging $6619.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$73K
What the payments were for
- Speaking & faculty fees$606%
- Food & beverage$96289%
- Education$656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $447 |
| Tandem Diabetes Care, Inc. | 2 | $175 |
| Ascendis Pharma Endocrinology Inc | 1 | $124 |
| BETA Bionics, Inc. | 1 | $124 |
| Dexcom, Inc. | 1 | $85 |
| Amgen | 1 | $71 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$371
- Yorvipath$124
- t:slim X2 Insulin Pump with Control-IQ$119
- Saxenda$109
- Wegovy$109
How this compares
$1,087 in reported general payments places this provider in the 55th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $268,998 |
| MounjaroTirzepatide | 85 | $97,373 |
| JardianceEmpagliflozin | 67 | $74,287 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $68,584 |
| TymlosAbaloparatide | 18 | $46,156 |
| Novolog FlexpenInsulin Aspart | 75 | $32,955 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $27,560 |
| TrulicityDulaglutide | 25 | $26,946 |
| Humalog Kwikpen U-100Insulin Lispro | 47 | $14,191 |
| Repatha SureclickEvolocumab | 15 | $13,744 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $12,243 |
| RybelsusSemaglutide | 11 | $11,657 |
| TirosintLevothyroxine Sodium | 28 | $6,286 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 71 | $6,145 |
| HumalogInsulin Lispro | 19 | $4,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $447 | $284,590197 claims |
| Sanofi-aventis U.S. LLCLantus | $60 | $3,73516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Vancouver
- Troy DillardVancouver$25K
- Katherine ChubinskayaVancouver$15K
- Saumya KumarVancouver$2K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.